CN103620022B - Nk细胞的扩增方法 - Google Patents

Nk细胞的扩增方法 Download PDF

Info

Publication number
CN103620022B
CN103620022B CN201280031188.5A CN201280031188A CN103620022B CN 103620022 B CN103620022 B CN 103620022B CN 201280031188 A CN201280031188 A CN 201280031188A CN 103620022 B CN103620022 B CN 103620022B
Authority
CN
China
Prior art keywords
cells
cell
expanding
positive
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280031188.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103620022A (zh
Inventor
米满吉和
原田结
齐藤智
矢崎雄一郎
冈本正人
石田尾武文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaia Biomedicine Inc
Original Assignee
Kyushu University NUC
Tella Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Tella Inc filed Critical Kyushu University NUC
Publication of CN103620022A publication Critical patent/CN103620022A/zh
Application granted granted Critical
Publication of CN103620022B publication Critical patent/CN103620022B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280031188.5A 2011-06-24 2012-06-20 Nk细胞的扩增方法 Active CN103620022B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-140725 2011-06-24
JP2011140725 2011-06-24
JP2012-021972 2012-02-03
JP2012021972A JP5572863B2 (ja) 2011-06-24 2012-02-03 Ｎｋ細胞の増幅方法
PCT/JP2012/065718 WO2012176796A1 (ja) 2011-06-24 2012-06-20 Ｎｋ細胞の増幅方法

Publications (2)

Publication Number Publication Date
CN103620022A CN103620022A (zh) 2014-03-05
CN103620022B true CN103620022B (zh) 2015-09-30

Family

ID=47422628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280031188.5A Active CN103620022B (zh) 2011-06-24 2012-06-20 Nk细胞的扩增方法

Country Status (9)

Country Link
US (1) US9404083B2 (enExample)
EP (1) EP2725100B1 (enExample)
JP (1) JP5572863B2 (enExample)
KR (1) KR101963920B1 (enExample)
CN (1) CN103620022B (enExample)
AU (1) AU2012274478B2 (enExample)
CA (1) CA2840161C (enExample)
MY (1) MY161389A (enExample)
WO (1) WO2012176796A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
JP6164650B2 (ja) * 2014-01-20 2017-07-19 国立大学法人九州大学 Ｎｋ細胞の調製方法
WO2015132415A1 (en) * 2014-03-07 2015-09-11 Emercell Sas Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US12398371B2 (en) 2015-01-27 2025-08-26 Korea Research Institute Of Bioscience Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN106222141B (zh) * 2016-10-17 2018-10-19 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
KR102765799B1 (ko) * 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019152663A1 (en) * 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
CN110628714B (zh) * 2018-06-21 2023-03-28 精准生技股份有限公司 用于体外扩增自然杀手细胞及自然杀手t细胞的无血清细胞培养液
CN109161527A (zh) * 2018-09-25 2019-01-08 深圳市五零生命科技有限公司 一种高效的nk细胞扩增方法
EP3892721A4 (en) * 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
WO2020152661A1 (ja) 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6838750B2 (ja) 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
JP6697611B2 (ja) * 2019-05-20 2020-05-20 米満　吉和 高活性ｎｋ細胞、およびその利用
CN111154721B (zh) * 2020-01-14 2023-10-17 深圳格泰赛尔生物科技有限公司 Nk细胞扩增方法
US20230040477A1 (en) * 2020-01-19 2023-02-09 Board Of Regents, The University Of Texas System T-cell death associated gene 8 (tdag8) modulation to enhance cellular cancer therapies
US12486492B2 (en) 2020-03-05 2025-12-02 Korea Research Institute Of Bioscience Method for producing memory-like NK cells with ability to express higher levels of NCRs, cytotoxicity, and IFN-γ than NK cells in human peripheral blood
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2025022372A1 (ja) * 2023-07-21 2025-01-30 株式会社ガイアバイオメディシン 細胞集団の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103901A3 (en) * 2006-03-06 2008-04-10 Us Gov Health & Human Serv Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
WO2008153150A1 (ja) * 2007-06-15 2008-12-18 Medinet Co., Ltd. Ｎｋ細胞を含む細胞集団の培養方法及び当該細胞集団の利用
WO2010013947A3 (ko) * 2008-07-29 2010-05-27 주식회사 녹십자 자연살해세포의 증식방법
JP2011517944A (ja) * 2008-04-09 2011-06-23 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) * 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
AU2003294930B2 (en) 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
JP2007297292A (ja) 2006-04-28 2007-11-15 Kyorin Pharmaceut Co Ltd １−アルコキシイソキノリン誘導体又はその水和物の製造方法
JP4275680B2 (ja) 2006-04-28 2009-06-10 裕 照沼 リンパ球の活性・増殖に係る培養方法
WO2008023874A1 (en) * 2006-08-23 2008-02-28 Binex Co., Ltd. Manufacturing method of activated lymphocytes for immunotherapy
JP4861420B2 (ja) 2006-08-28 2012-01-25 久光製薬株式会社 爪用貼付剤
AU2008307633C1 (en) * 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
CN102597223B (zh) * 2009-09-11 2017-05-10 宝生物工程株式会社 生产天然杀伤细胞的方法
EP2519239B1 (en) 2009-12-29 2017-03-08 Gamida Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
JP2011239701A (ja) 2010-05-14 2011-12-01 Tella Inc 樹状細胞の培養方法
KR101039843B1 (ko) 2010-08-30 2011-06-09 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법
JP5840876B2 (ja) 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103901A3 (en) * 2006-03-06 2008-04-10 Us Gov Health & Human Serv Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
WO2008153150A1 (ja) * 2007-06-15 2008-12-18 Medinet Co., Ltd. Ｎｋ細胞を含む細胞集団の培養方法及び当該細胞集団の利用
JP2011517944A (ja) * 2008-04-09 2011-06-23 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
WO2010013947A3 (ko) * 2008-07-29 2010-05-27 주식회사 녹십자 자연살해세포의 증식방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A New Method for In Vitro Expansion of Cytotoxic Human CD3_CD56_ Natural Killer Cells;Stefan Carlens et al;《Human Immunology》;20011231;1092-1098 *
Immature NK Cells, Capable of Producing IL-22, Are Present in Human Uterine Mucosa;Victoria Male et al;《J Immunol》;20100827;3913-3918 *

Also Published As

Publication number Publication date
JP2013027385A (ja) 2013-02-07
JP5572863B2 (ja) 2014-08-20
EP2725100A4 (en) 2015-01-07
US20140120072A1 (en) 2014-05-01
MY161389A (en) 2017-04-14
EP2725100A1 (en) 2014-04-30
US9404083B2 (en) 2016-08-02
EP2725100B1 (en) 2019-09-04
AU2012274478A1 (en) 2014-02-20
KR20140051263A (ko) 2014-04-30
CN103620022A (zh) 2014-03-05
CA2840161A1 (en) 2012-12-27
KR101963920B1 (ko) 2019-03-29
AU2012274478B2 (en) 2017-03-30
AU2012274478A8 (en) 2016-07-28
WO2012176796A1 (ja) 2012-12-27
HK1190432A1 (en) 2014-07-04
CA2840161C (en) 2019-02-12

Similar Documents

Publication Publication Date Title
CN103620022B (zh) Nk细胞的扩增方法
EP3000876B1 (en) Method for preparing nk cells
CN110603320B (zh) 高活性nk细胞及其应用
CN114958738A (zh) 用于生产TCRγδ+T细胞的方法
TWI854974B (zh) 表現趨化因子受體及細胞接著分子之cd3陰性細胞之集團、及其用途及其製造方法
JP5989016B2 (ja) Ｎｋ細胞の増幅方法
TWI757709B (zh) 含有nk細胞之細胞集團之製造方法
JP6164650B2 (ja) Ｎｋ細胞の調製方法
JP6697611B2 (ja) 高活性ｎｋ細胞、およびその利用
JP2020108405A (ja) 高活性ｎｋ細胞、およびその利用
HK1190432B (en) Method for amplifying nk cells
JP2023153286A (ja) Ｎｋ細胞を含む細胞集団の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190432

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1190432

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170210

Address after: Fukuoka County, Japan

Patentee after: Kyushu University

Patentee after: Gaia biopharmaceutical Co., Ltd.

Address before: Fukuoka County, Japan

Patentee before: Kyushu University

Patentee before: TELLA INC

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200929

Address after: Fukuoka County, Japan

Patentee after: Gaia biopharmaceutical Co.,Ltd.

Address before: Fukuoka County, Japan

Patentee before: National University Corporation Kyushu University

Patentee before: Gaia biopharmaceutical Co.,Ltd.